Terms: = Endocrine gland cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
13 results:
1. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
2. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
[TBL] [Abstract] [Full Text] [Related]
4. SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition.
Sundararajan V; Tan M; Tan TZ; Ye J; Thiery JP; Huang RY
Sci Rep; 2019 Jun; 9(1):8295. PubMed ID: 31165775
[TBL] [Abstract] [Full Text] [Related]
5. Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3.
Tracht J; Zhang K; Peker D
J Histochem Cytochem; 2017 Jul; 65(7):399-405. PubMed ID: 28651471
[TBL] [Abstract] [Full Text] [Related]
6. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Lee HS; Park SB; Kim SA; Kwon SK; Cha H; Lee DY; Ro S; Cho JM; Song SY
Sci Rep; 2017 Jan; 7():41615. PubMed ID: 28134290
[TBL] [Abstract] [Full Text] [Related]
7. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas.
Zang X; Sullivan PS; Soslow RA; Waitz R; Reuter VE; Wilton A; Thaler HT; Arul M; Slovin SF; Wei J; Spriggs DR; Dupont J; Allison JP
Mod Pathol; 2010 Aug; 23(8):1104-12. PubMed ID: 20495537
[TBL] [Abstract] [Full Text] [Related]
8. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Manuyakorn A; Paulus R; Farrell J; Dawson NA; Tze S; Cheung-Lau G; Hines OJ; Reber H; Seligson DB; Horvath S; Kurdistani SK; Guha C; Dawson DW
J Clin Oncol; 2010 Mar; 28(8):1358-65. PubMed ID: 20142597
[TBL] [Abstract] [Full Text] [Related]
9. Nicotinamide phosphoribosyltransferase and prostaglandin H2 synthase 2 are up-regulated in human pancreatic adenocarcinoma cells after stimulation with interleukin-1.
Bauer L; Venz S; Junker H; Brandt R; Radons J
Int J Oncol; 2009 Jul; 35(1):97-107. PubMed ID: 19513556
[TBL] [Abstract] [Full Text] [Related]
10. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers.
Wei Y; Xia W; Zhang Z; Liu J; Wang H; Adsay NV; Albarracin C; Yu D; Abbruzzese JL; Mills GB; Bast RC; Hortobagyi GN; Hung MC
Mol Carcinog; 2008 Sep; 47(9):701-6. PubMed ID: 18176935
[TBL] [Abstract] [Full Text] [Related]
11. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
[TBL] [Abstract] [Full Text] [Related]
12. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors.
Barbieri F; Cagnoli M; Ragni N; Foglia G; Bruzzo C; Pedullà F; Alama A
Clin Cancer Res; 1999 Jul; 5(7):1837-42. PubMed ID: 10430089
[TBL] [Abstract] [Full Text] [Related]
13. nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters.
Scambia G; Ferrandina G; Marone M; Benedetti Panici P; Giannitelli C; Piantelli M; Leone A; Mancuso S
J Clin Oncol; 1996 Feb; 14(2):334-42. PubMed ID: 8636741
[TBL] [Abstract] [Full Text] [Related]
